Surgical Critical Care and Emergency Surgery. Группа авторов
for the treatment of patients in the ICU and appropriate therapy decreases mortality as well as antibiotic resistance. The Surviving Sepsis campaign highlights starting antibiotics within an hour of emergency room admission or suspicion of sepsis and appropriate antimicrobial coverage of the suspected source. Sepsis of unknown origin requires active therapy against gram‐positive and gram‐negative pathogens. Common regimens are cefepime and vancomycin or piperacillin‐tazobactam and vancomycin. Quinolones only (Answer A) provide narrow coverage for gram‐negative bacteria and would not be appropriate for a septic patient of unknown origin. The Short Course Antimicrobial Therapy for Intraabdominal Infection (STOP‐IT) trial showed there was no difference in outcomes between 4 days and 8 days of antibiotics after source control had been achieved. Another study showed longer antibiotic courses led to increased risk of secondary infections and higher mortality. Answer B is incorrect because the patient only needs 4 days of antibiotics. It is important to de‐escalate antibiotics as soon as possible (Answer D). As vancomycin is used to cover gram‐positive bacteria, and specifically methicillin‐resistant Staph aureus (MRSA), vancomycin should be stopped as soon as it is known that the organism is not MRSA (Answer C). Answer E is incorrect because it is important to maintain minimum inhibitory concentration (MIC) of antibiotics. To achieve this, many beta‐lactamase antibiotics (cefepime, piperacillin) have been switched to extended infusions.Answer: DCampion M, Scully G . Antibiotic use in the intensive care unit: optimization and de‐escalation. J Intensive Care Med. 2018; 33 (12):647–655.
19 An 82‐year‐old man was started on clindamycin for left lower extremity cellulitis. Eight days after starting antibiotics, he presents to the emergency department with severe diarrhea, fever, abdominal pain, and emesis. His vitals are: HR 130 bpm, BP 90/50 mmHg, and his WBC is 35 000. C. difficile PCR is positive. What is the best management of his C. difficile infection?Discontinue antibiotics onlyDiscontinue antibiotics and start IV vancomycinDiscontinue antibiotics and start PO metronidazoleDiscontinue antibiotics and start PO vancomycinDiscontinue antibiotics and start IV rifampinClostridium difficile infection (CDI) has increased in frequency and severity over the last decade. Minimizing antibiotics, especially clindamycin and fluoroquinolones, is the cornerstone of prevention. This patient has severe C. difficile infection, as he presents in septic shock. Based on current treatment regimens, the previous antibiotics need to be stopped and vancomycin 125 mg orally four times a day should be started. Discontinuation of antibiotics only (Answer A) is incorrect as this patient needs additional treatment since he is in septic shock. Answer B is incorrect since vancomycin should be given via the oral (PO) route and not the IV route. Vancomycin administered IV does not reach therapeutic levels in the colonic lumen. Answer C is incorrect since oral metronidazole is only for mild disease or if oral vancomycin is unavailable or contraindicated. Metronidazole, administered either orally or IV, only reaches low therapeutic levels in the colon; therefore, even a slightly elevated MIC of C. difficile for metronidazole may lead to therapy failure. Multiple studies have shown that monotherapy of IV metronidazole is inferior to monotherapy PO vancomycin for treatment of Clostridium difficile. If the patient advances to fulminant colitis, the regimen would be vancomycin 500 mg orally or via nasogastric tube four times a day and metronidazole 500 mg intravenously every eight hours. Surgery would also be indicated with fulminant colitis. Rifampin (Answer E) is incorrect because while it has been used previously, data is lacking on its efficacy and is currently not recommended.Findoxamin, a novel macrolide antibiotic, bezlotoxumab, a monoclonocal antibody against toxin TCDB, and fecal microbiota transplant, are gaining popularity, especially in recurrent infections. Surgical treatment, typically a total colectomy, are reserved for those patients with fulminant colitis, though patient selection and timing of operation can be challenging.Answer: DGuh AY, Kutty PK . Clostridioides difficile infection. Ann Intern Med. 2018; 169 (7):ITC49–ITC64.Goldenberg JZ, Yap C, Lytvyn L, et al. Probiotics for the prevention of clostridium difficile‐ associated diarrhea in adults and children. The Cochrane Database of Systematic Reviews. 2017 Dec; 19(12):CD006095Bignardi GE . Risk factors for clostridium difficile infection. J Hosp Infect. 1998; 40(1):1–15. PMID: 9777516.Bowman JA, Uteer GH . Evolving strategies to manage clostridium difficile infections. J Gastrointest Surg. 2020; 24(2):484–91.
20 A 55‐year‐old otherwise healthy man presents to the emergency department with a large incarcerated umbilical hernia. He is brought to the operating room for open surgical repair. The patient was paralyzed with rocuronium to assist the reduction of the hernia. The surgery goes well and you tell the anesthesiologist that you are finished closing the fascia; however, a dose of rocuronium was just administered. Which statement is true regarding neuromuscular blocking agents (NMBAs) reversal?Neostigmine is an anticholinergic drug that is often used in conjunction with agents such as atropine and glycopyrrolate. The reversal agent available for succinylcholine is edrophonium.The mechanism of action of sugammadex includes chelating the NMBAs, making them inactive and removing them from the neuromuscular junction.Sugammadex is slower at reversing NMBA‐induced paralysis than both neostigmine and edrophonium.Acetylcholinesterase inhibitors are reversal agents available for depolarizing NMBAs.Neuromuscular blocking agents (NMBAs) can be broken down into two main classes: depolarizing and nondepolarizing agents. Succinylcholine is the only member of the depolarizing class of NMBAs and there is no reversal agent available (Answer B). The nondepolarizing NMBAs are rocuronium, pancuronium, vecuronium, atracurium, and its isomer, cisatracurium. Neostigmine and other acetylcholinesterase inhibitors (Answer A – incorrect choice because neostigmine is an acetylcholinesterase inhibitor) were the only reversal agents available for nondepolarizing NMBAs (Answer E). These agents increase the endogenous amount of acetylcholine available for binding at the neuromuscular junction, thus, competitively counteract the NMBAs effect. Sugammadex is a novel class of drugs called selective relaxant binding agents (SRBAs). The mechanism of action is twofold: (1) encapsulating (chelating) steroid backboned NMBAs (rocuronium, pancuronium, vecuronium) making them inactive and removing them from the neuromuscular junction, thus restoring muscle function; (2) the NMBAs that are already bound to nicotinic receptors will dissociate from the receptor (Answer C). Sugammadex exerts its effect by forming very tight complexes at a 1:1 ratio with aminosteroid muscle relaxants (rocuronium > vecuronium >> pancuronium). The intermolecular (van der Waals’) forces, thermodynamic (hydrogen) bonds and hydrophobic interactions make the sugammadex–rocuronium complex very tight. The resulting reduction in free‐rocuronium plasma concentration creates a gradient between the tissue compartment (including the neuromuscular junction) and plasma‐free rocuronium moves from tissue to plasma, with a reduction in nicotinic receptor occupancy at the neuromuscular junction. Multiple trials have found sugammadex is faster at reversing rocuronium‐ and vecuronium‐induced paralysis than both neostigmine and edrophonium (Answer D) while having similar adverse event profiles as the traditional cholinesterase inhibitors. Atropine and glycopyrrolate (Answer A) are both anticholinergic drugs that are often used in conjunction with cholinesterase inhibitors (neostigmine and edrophonium) to help offset their cholinergic effects such as bradycardia and excessive salivation. They have no role in NMBA reversal when used by themselves.Answer: CAbrishami A, Ho J, Wong J, et al. Sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. The Cochrane Library. 2009 Oct; 7(4):CD007362.Welliver, M, McDonough J, Kalynych N, et al. Discovery, development, and clinical application of sugammadex sodium, a selective relaxant binding agent. Drug Des Devel Ther. 2008; 2 : 49–59.Keating, GM Sugammadex: a review of neuromuscular blockade reversal. Drugs. 2016; 76 (10):1041–1052.
21 A 42‐year‐old man with no past medical history was in a motor vehicle crash and sustained a large subdural hematoma. The patient is intubated and taken to the operating room for a decompressive craniotomy. On postoperative day 6 while still intubated, the patient develops thick purulent‐looking secretions, has a WBC 13 000, and a fever to 38.4°C. Blood cultures, urine cultures, and bronchial alveolar lavage are obtained. What should be the empiric therapy for his suspected ventilator‐associated pneumonia?Vancomycin and ciprofloxacinVancomycin and gentamicinVancomycin and cefepimeCeftriaxone and azithromycinAmpicillin‐sulbactam and doxycyclinePer 2016 guidelines, antibiotic coverage for ventilator‐associated pneumonia (VAP) should include an active agent against MRSA when risk factors for antimicrobial resistance is present (prior IV antibiotics within 90 days, septic shock at time of VAP, ARDS preceding VAP, 5 or more days of hospitalization prior to VAP, acute renal replacement therapy). This patient most likely received antibiotics prior to his craniotomy and